Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21124971 | 0.88 | AKR1C3 (0.41) | SLC6A3DPP4POLBL3MBTL1AKR1C3 | |
| SCHEMBL21466515 | 0.84 | UBE2M (0.38) | AKR1C3AKR1C2SLC6A4 | |
| SCHEMBL21124958 | 0.82 | AKR1C3 (0.46) | POLBL3MBTL1AKR1C3AKR1C2S1PR1 | |
| SCHEMBL22561848 | 0.81 | RORC (0.38) | ADRB2 | |
| SCHEMBL20178578 | 0.80 | ALDH1A1 (0.43) | PPARGPPARAAKR1C3AKR1C2 | |
| SCHEMBL19464644 | 0.78 | AR (0.53) | — | |
| SCHEMBL19820209 | 0.77 | AKR1C3 (0.42) | SLC6A3DPP4PTGESALOX5PPARG | |
| SCHEMBL21124509 | 0.76 | PDE2A (0.39) | AKR1C3AKR1C2S1PR1ADRB2 | |
| SCHEMBL20178581 | 0.76 | THRA (0.41) | S1PR1 | |
| SCHEMBL21125230 | 0.75 | AKR1C3 (0.43) | SLC6A3DPP4PTGESALOX5PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398703-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SLC6A3 929/4885DPP4 747/4885PTGES 341/4885 |
| US-10398703-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | SLC6A3 929/4885DPP4 747/4885PTGES 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.